BACKGROUND: Two doses of trivalent inactivated influenza vaccine (TIV) are recommended for children <9 years old receivingvaccine for the first time, but compliance is suboptimal. This study assessed the need for a second dose of TIV in this age group. METHODS: In this prospective, open-label study, 232 influenza vaccine-naive 5-8-year-olds enrolled in a health maintenance organization received 2 doses of TIV in fall 2004. Serum for antibody titer measurement was obtained at 3 time points (n = 222). Parents completed diaries for 5 days. RESULTS: Both doses of vaccine were well tolerated. The strongest predictor of a protective antibody response (> or =1 : 40) after 1 dose of TIV was baseline seropositive status. In multivariate analysis adjusting for age, sex, and baseline serostatus, the proportion of children with protective antibody responses was significantly higher after 2 doses than after 1 dose of TIV for each antigen (P < .001, for A/H1N1; P = .01, for A/H3N2; P < .001, for B). Age and sex were not independently predictive of a protective antibody response. Over one-third of children had antibody responses <1:40 for the type B vaccine component, even after 2 doses. CONCLUSIONS: The present study supports the need for 2 doses of TIV in 5-8-year-olds receiving TIV for the first time. Efforts to increase compliance with the 2-dose recommendation are warranted.
RCT Entities:
BACKGROUND: Two doses of trivalent inactivated influenza vaccine (TIV) are recommended for children <9 years old receiving vaccine for the first time, but compliance is suboptimal. This study assessed the need for a second dose of TIV in this age group. METHODS: In this prospective, open-label study, 232 influenza vaccine-naive 5-8-year-olds enrolled in a health maintenance organization received 2 doses of TIV in fall 2004. Serum for antibody titer measurement was obtained at 3 time points (n = 222). Parents completed diaries for 5 days. RESULTS: Both doses of vaccine were well tolerated. The strongest predictor of a protective antibody response (> or =1 : 40) after 1 dose of TIV was baseline seropositive status. In multivariate analysis adjusting for age, sex, and baseline serostatus, the proportion of children with protective antibody responses was significantly higher after 2 doses than after 1 dose of TIV for each antigen (P < .001, for A/H1N1; P = .01, for A/H3N2; P < .001, for B). Age and sex were not independently predictive of a protective antibody response. Over one-third of children had antibody responses <1:40 for the type B vaccine component, even after 2 doses. CONCLUSIONS: The present study supports the need for 2 doses of TIV in 5-8-year-olds receiving TIV for the first time. Efforts to increase compliance with the 2-dose recommendation are warranted.
Authors: Julie E Ledgerwood; Zonghui Hu; Pamela Costner; Galina Yamshchikov; Mary E Enama; Sarah Plummer; Cynthia S Hendel; Lasonji Holman; Brenda Larkin; Ingelise Gordon; Robert T Bailer; Donald M Poretz; Uzma Sarwar; Alisha Kabadi; Richard Koup; John R Mascola; Barney S Graham Journal: Contemp Clin Trials Date: 2015-08-12 Impact factor: 2.226
Authors: Vinay Rambal; Karin Müller; Chantip Dang-Heine; Arne Sattler; Mikalai Dziubianau; Benjamin Weist; Si-Hong Luu; Alexandra Stoyanova; Peter Nickel; Andreas Thiel; Avidan Neumann; Brunhilde Schweiger; Petra Reinke; Nina Babel Journal: Med Microbiol Immunol Date: 2013-09-22 Impact factor: 3.402
Authors: Ming-Wei Chen; Ting-Jen Rachel Cheng; Yaoxing Huang; Jia-Tsrong Jan; Shiou-Hwa Ma; Alice L Yu; Chi-Huey Wong; David D Ho Journal: Proc Natl Acad Sci U S A Date: 2008-09-02 Impact factor: 11.205
Authors: C R Baskin; H Bielefeldt-Ohmann; A García-Sastre; T M Tumpey; N Van Hoeven; V S Carter; M J Thomas; S Proll; A Solórzano; R Billharz; J L Fornek; S Thomas; C-H Chen; E A Clark; Kaja Murali-Krishna; M G Katze Journal: J Virol Date: 2007-08-22 Impact factor: 5.103
Authors: E Young Bae; Ui Yoon Choi; Hyo Jin Kwon; Dae Chul Jeong; Jung Woo Rhim; Sang Hyuk Ma; Kyung Il Lee; Jin Han Kang Journal: Clin Vaccine Immunol Date: 2013-03-27
Authors: Mark G Thompson; Jessie Clippard; Joshua G Petrie; Michael L Jackson; Huong Q McLean; Manjusha Gaglani; Evelyn C Reis; Brendan Flannery; Arnold S Monto; Lisa Jackson; Edward A Belongia; Kempapura Murthy; Richard K Zimmerman; Swathi Thaker; Alicia M Fry Journal: Pediatr Infect Dis J Date: 2016-03 Impact factor: 2.129